IP Library Granted Patent US 10,443,038
Granted Patent B2
US 10,443,038 · App. 16/029,892 · Granted Oct 15, 2019

Agents and methods for treating and preventing seborrheic keratosis

Inventors: Anna I. Mandinova (Newton, MA); Sam W. Lee (Newton, MA); Victor A. Neel (Providence, RI)
Assignee: THE GENERAL HOSPITAL CORPORATION
C12N5/0629A61K31/352A61K31/353A61K31/437A61K31/4439A61K31/475A61K31/4745A61K31/496A61K31/7076A61K31/713A61K45/06C07K16/40C12N15/1137C12Y207/11001C12Y304/21004C12Y304/24004G01N33/5044A61K2039/505C12N2310/14C12N2501/734G01N2333/912G01N2500/10G01N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,443,038
App. No.
16/029,892
Granted
Oct 15, 2019
Kind
B2
Abstract

Provided herein are methods and assays for isolating and culturing seborrheic keratosis cells ex vivo. Also provided herein are screening assays using cultured seborrheic keratosis cells and methods for treating seborrheic keratosis in a subject.

Claims (7)

1. A method for inducing apoptosis in a seborrheic keratosis cell, the method comprising contacting a seborrheic keratosis cell with an effective amount of an ATP-competitive Akt inhibitor, thereby inducing apoptosis in the cell.

2. The method of claim 1 , wherein the effective amount of the composition does not substantially affect the survival of normal keratinocytes.

3. A method for treating a seborrheic keratosis in a subject, the method comprising administering a composition comprising a therapeutically effective amount of an siRNA that targets Akt to a subject having seborrheic keratosis.

4. The method of claim 3 , wherein the composition is applied topically or administered systemically.

5. The method of claim 3 , wherein the therapeutically effective amount of the composition does not substantially affect the survival or normal keratinocytes.

6. The method of claim 3 , wherein the composition further comprises a pharmaceutically acceptable carrier.

7. The method of claim 1 , wherein the ATP-competitive Akt inhibitor comprises A-443654, AT7867, or GSK690693.

Continuity (5)
Continuation 15482899 · Apr 10, 2017
Continuation 15254344 · Sep 1, 2016
Division 14395737
Provisional Application 61638684 · Apr 26, 2012
Related Publication 20180320132A1 · Nov 8, 2018
Cited By (1)
US 12,551,509